A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer.
Authors
Hickish, TCassidy, J
Propper, D
Chau, I
Falk, S
Ford, H
Iveson, T
Braun, Michael S
Potter, V
Macpherson, I
Finnigan, H
Lee, C
Jones, H
Harrison, M
Affiliation
Poole Hospital and Bournemouth University, Longfleet Road, Poole, Dorset BH15 2JB, UK.Issue Date
2014-12
Metadata
Show full item recordAbstract
This randomised phase II trial aimed to compare efficacy of the irreversible ErbB family blocker, afatinib, with cetuximab in patients with KRAS wild-type metastatic colorectal adenocarcinoma (mCRC) with progression following oxaliplatin- and irinotecan-based regimens. Efficacy in patients with KRAS mutations was also evaluated.Citation
A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. 2014, 50 (18):3136-44 Eur J CancerJournal
European Journal of CancerDOI
10.1016/j.ejca.2014.08.008PubMed ID
25441408Type
ArticleLanguage
enISSN
1879-0852ae974a485f413a2113503eed53cd6c53
10.1016/j.ejca.2014.08.008